Monte Rosa Therapeutics Inc(GLUE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 4:00 PM ET (Korea 10/30 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.91 | Insider Own | 29.47% | Shs Outstand | 85.2M | Perf Week | -2.16% |
| Market Cap | 0.93B | Forward P/E | - | EPS next Y | -31.12% | Insider Trans | -0.49% | Shs Float | 60.2M | Perf Month | -8.89% |
| Enterprise Value | 0.34B | PEG | - | EPS next Q | -0.21 | Inst Own | 89.39% | Short Float | 34.34% | Perf Quarter | -34.2% |
| Income | -0.16B | P/S | 32.28 | EPS this Y | -208.79% | Inst Trans | 6.45% | Short Ratio | 14.67 | Perf Half Y | -43.24% |
| Sales | 0.03B | P/B | 1.9 | EPS next 5Y | - | ROA | -30.67% | Short Interest | 20.66M | Perf YTD | -30.68% |
| Book/sh | 5.72 | P/C | 1.49 | EPS past 3/5Y | 41.29% 10.62% | ROE | -42.66% | 52W High | -57.82% ($25.77) | Perf Year | -13.04% |
| Cash/sh | 7.28 | P/FCF | - | Sales past 3/5Y | - | ROIC | -30.95% | 52W Low | 12.29% ($9.68) | Perf 3Y | 291.01% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -646.52% | Gross Margin | 71.72% | Volatility(W/M) | 4.33% 6.06% | Perf 5Y | -53.65% |
| Dividend TTM | - | EV/Sales | 11.98 | Sales Y/Y TTM | -83.86% | Oper. Margin | -633.04% | ATR (14) | 0.61 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 10.58 | EPS Q/Q | -185.83% | Profit Margin | -560.85% | RSI (14) | 45.91 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 10.58 | Sales Q/Q | -61.33% | SMA20 | 3.73% ($10.48) | Beta | 1.39 | Target Price | $26.88 |
| Payout | - | Debt/Eq | 0.08 | Earnings | 2026/8/6 | SMA50 | -10.59% ($12.16) | Rel Volume | 0.93 | Prev Close | $10.85 |
| Employees | 150 | LT Debt/Eq | 0.07 | EPS/Sales Surpr. | -13.01% -30.38% | SMA200 | -37.7% ($17.45) | Avg Volume(3M) | 1.41M | Price | $10.87 |
| IPO | 2021/6/24 | Option/Short | Yes/Yes | Trades | 7767 | Volume | 1,307,286 | Change | 0.18% |
🧬 Monte Rosa Therapeutics (GLUE) is a US clinical-stage biotech company developing molecular glue degraders. It owns a novel drug platform that targets and degrades proteins previously considered undruggable, and is expanding its pipeline in autoimmune, inflammatory, and oncology indications. Through collaborations with global pharmaceutical companies such as Novartis and Roche, Monte Rosa has validated its technology, positioning it as a next-generation targeted protein degradation company.
Over the past 1 year, on the lower side
58% below its 1-year high.
Traded about as much as usual. That is 93% of its average volume.
GLUE has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -208.8% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $3,228. Peers typically go for $1,217.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -53.6%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
34.3% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #166 of 594 in the industry
Based on market cap of $927M.
MGTX#164 MeiraGTx Holdings plc $932M PER 13.8 
ORIC#165 ORIC Pharmaceuticals Inc $932M PER - GLUE#166 Monte Rosa Therapeutics Inc $927M PER - 
ALMS#167 Alumis Inc $922M PER - 
ANRO#168 Alto Neuroscience Inc $921M PER - 
FAQ
What kind of company is GLUE?
GLUE belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of GLUE?
The market cap of GLUE is approximately $927M, ranking 2,648 within its sector.
What is the 52-week high and low for GLUE?
GLUE has recorded a 52-week high of $25.77 and a low of $9.68.
